- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Chelsee Jensen Explains Implementing Biosimilars in Small vs Large Practices
Chelsee Jensen, PharmD, pharmaceutical formulary manager at Mayo Clinic, explains how the process of implementing biosimilars may differ depending on practice size.
Chelsee Jensen, PharmD, pharmaceutical formulary manager at the Mayo Clinic, explains how the process of implementing biosimilars may differ depending on practice size.
Transcript
How does implementing tools for increasing biosimilar use differ between smaller and larger practices?
So, at a smaller practice site where maybe you're operating only in 1 state or maybe you just have a few commercial payers, or even if a majority of your payer mix is government payers, you can probably adopt biosimilars in a full fledge swoop. So, all at once vs our approach, which has been a phased approach of initiating new patients on biosimilars and then choosing a biosimilar at prior authorization renewal. So, if you're in a smaller health system, and you're able to pick a preferred product—because, again, maybe your payer landscape is more standardized—then you can have one set implementation date, have reduced inventory burden, and just improve workflows going forward.
AI Meets Medicare: Inside CMS’s WISeR Model With Sanjay Doddamani, MD, MBA, Part 2
August 5th 2025In this second part of his interview with The American Journal of Managed Care®, Sanjay Doddamani, MD, MBA, a former senior advisor to CMMI and founder and CEO of Guidehealth, continues a dialogue on the future of value-based care and the promise—and limits—of AI-enabled innovation, reflecting on challenges like rising Medicare costs and patients’ growing financial burdens.
Read More
